Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Gains from Sales and Divestitures: 2016-2025

Historic Gains from Sales and Divestitures for BIO-TECHNE (TECH) over the last 10 years, with Jun 2025 value amounting to $134,000.

  • BIO-TECHNE's Gains from Sales and Divestitures rose 3.88% to $134,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $134,000, marking a year-over-year increase of 3.88%. This contributed to the annual value of $134,000 for FY2025, which is 3.88% up from last year.
  • According to the latest figures from FY2025, BIO-TECHNE's Gains from Sales and Divestitures is $134,000, which was up 3.88% from $129,000 recorded in FY2024.
  • BIO-TECHNE's Gains from Sales and Divestitures' 5-year high stood at $206,000 during FY2021, with a 5-year trough of $123,000 in FY2023.
  • For the 3-year period, BIO-TECHNE's Gains from Sales and Divestitures averaged around $128,667, with its median value being $129,000 (2024).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first spiked by 303.92% in 2021, then declined by 29.61% in 2022.
  • Over the past 5 years, BIO-TECHNE's Gains from Sales and Divestitures (Yearly) stood at $206,000 in 2021, then declined by 29.61% to $145,000 in 2022, then fell by 15.17% to $123,000 in 2023, then grew by 4.88% to $129,000 in 2024, then rose by 3.88% to $134,000 in 2025.